ArticleDiscover oncology2025
Efficacy and safety of anlotinib maintenance therapy in limited-stage small cell lung cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEffective maintenance therapy options after first-line chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) remain limited. Anlotinib, a multi-target tyrosine kinase inhibitor, was evaluated for its efficacy and safety in this setting.
methodsIn this single-center, prospective, randomized controlled trial, 60 LS-SCLC patients who had completed first-line chemoradiotherapy were enrolled and randomly assigned (1:1) to receive either anlotinib maintenance therapy or best supportive care. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included objective response rate (ORR), safety, and quality of life (QoL).
resultsThe anlotinib group demonstrated a significantly prolonged median PFS compared to the control group. Furthermore, patients in the anlotinib group experienced earlier and more significant improvement in QoL, and a strong positive correlation was observed between QoL scores and OS. The safety profile of anlotinib was consistent with its known characteristics, with hypertension and proteinuria being the most common adverse events, which were manageable through dose modifications.
conclusionAnlotinib as maintenance therapy significantly improved PFS and QoL in patients with LS-SCLC, with a manageable safety profile. This study provides initial evidence supporting the potential role of anlotinib in this treatment paradigm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.